Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Duality BiotherapeuticsFRA:4ZB +6.49%19 Earnings Yield (Joel Greenblatt) % is -12.01% as of Jun. 2026. GuruFocus rates FRA:4ZB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,331 Biotechnology companies, Duality Biotherapeutics ranks worse than 53.49% on this metric.
Duality Biotherapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was €1,472.6 Mil.
Duality Biotherapeutics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Jun. 2026. Therefore, GuruFocus does not calculate Duality Biotherapeutics's Earnings Yield (Joel Greenblatt) at this moment.
The historical rank and industry rank for Duality Biotherapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
FRA:4ZB'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -40.67 Med: -10.87 Max: -3.01
Current: -12.3
During the past 4 years, the highest Earnings Yield (Joel Greenblatt) of Duality Biotherapeutics was -3.01%. The lowest was -40.67%. And the median was -10.87%.
FRA:4ZB's Earnings Yield (Joel Greenblatt) % is ranked worse than 53.49% of 1331
companies
in the Biotechnology industry
Industry Median: -10.5
vs FRA:4ZB: -12.30
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Duality Biotherapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Duality Biotherapeutics Earnings Yield (Joel Greenblatt) % Related Terms
Duality Biotherapeutics Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Duality Biotherapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Duality Biotherapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duality Biotherapeutics Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Duality Biotherapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Duality Biotherapeutics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Duality Biotherapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
What does a Earnings Yield (Joel Greenblatt) % of -12.01% mean?
Duality Biotherapeutics (FRA:4ZB) has a Earnings Yield (Joel Greenblatt) % of -12.01% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Duality Biotherapeutics and its competitors. According to the industry distribution chart, Duality Biotherapeutics ranks #712 out of 1331 companies in the Biotechnology industry, placing it in the top 53.5%.
Is Duality Biotherapeutics' Earnings Yield (Joel Greenblatt) % too high?
Duality Biotherapeutics' current Earnings Yield (Joel Greenblatt) % is -12.01%. Based on the distribution chart, Duality Biotherapeutics ranks #712 out of 1331 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Duality Biotherapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' Earnings Yield (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Duality Biotherapeutics ranks #712 out of 1331 companies for Earnings Yield (Joel Greenblatt) %. This places Duality Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Duality Biotherapeutics and its competitors. Duality Biotherapeutics's current Earnings Yield (Joel Greenblatt) % is -12.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (FRA:4ZB) has a current Earnings Yield (Joel Greenblatt) % of -12.01%. The current Earnings Yield (Joel Greenblatt) % is -12.01%. Duality Biotherapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Duality Biotherapeutics (FRA:4ZB), the current Earnings Yield (Joel Greenblatt) % is -12.01% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
19GF Score
Get the complete analysis for FRA:4ZB
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4ZB has been successfully added to your 
